Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic CRISPR-edited anti-CLL-1 CAR-T cells CB-012

A preparation of allogeneic, off-the-shelf T lymphocytes genetically modified and clustered regularly interspaced short palindromic repeats (CRISPR)-edited to contain the deletion of the TRAC gene, the site-specific insertion of a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) C-type-lectin-like molecule-1 (CLL-1; CLL1; C-type lectin domain family 12 member A; CLEC12A; CD371) into the TRAC gene, the knockout of programmed death 1 (PD-1; PDCD1; CD279; programmed cell death-1), the deletion of the B2M gene, and the site-specific insertion of a gene encoding a B2M-HLA-E-peptide fusion into the B2M gene, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic CRISPR-edited anti-CLL-1 CAR-T cells CB-012 recognize and bind to CLL-1-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CLL-1-expressing tumor cells. Knock out of the TRAC gene eliminates the endogenous T-cell receptors (TCRs), thereby preventing graft-versus-host disease (GvHD). PD-1, an immune checkpoint receptor expressed on T cells, plays a key role in tumor immune evasion by binding to its ligand programmed death ligand 1 (PD-L1; cluster of differentiation 274; CD274; programmed cell death-1 ligand 1) expressed on tumor cells. By removing PD-1 from T cells, PD-1-mediated signaling is halted which may decrease T-cell exhaustion and may enhance T-cell activity against the CLL-1-expressing tumor cells. The B2M protein is removed to eliminate endogenous HLA class I expression on the surface of the CB-012 CAR-T cells, which protects the CAR-T cells from host T-cell rejection. The B2M-HLA-E fusion protein is inserted to protect the CAR-T cells from host natural killer (NK) cell rejection. CLL-1, a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed in leukemic stem cells (LSCs) and plays an important role in disease progression and relapse for myeloid malignancies.
Synonym:allogeneic anti-CLL-1 CAR T cells CB-012
allogeneic anti-CLL-1 CAR-T cells CB-012
Code name:CB 012
CB-012
CB012
Search NCI's Drug Dictionary